Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BETAXON (levobetaxolol HCl)
BETAXON · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Brinzolamide suspension, 1% | EXPERIMENTAL | Dosed twice daily for 12 weeks |
| Levobetaxolol suspension, 0.5% | EXPERIMENTAL | Dosed twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| BETAXON (levobetaxolol HCl) | DRUG | levobetaxolol suspension, 0.5% |
| AZOPT (brinzolamide) | DRUG | brinzolamide suspension, 1% |
INCLUSION: * Children 5 years old and younger * require treatment for glaucoma or ocular hypertension * vision is 20/80 or better * cup-to-disc ratio of 0.8 or less EXCLUSION: * do not have abnormal fixation * IOP greater than 36 mm Hg * significant retinal disease * penetrating keratoplasty * se...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
BETAXON is an ophthalmology medicine being studied for the treatment of glaucoma and ocular hypertension. It is a small molecule product developed by Alcon Inc. (ticker ALC). Its clinical development has focused on use in pediatric patients with these eye conditions.
BETAXON is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor behind the clinical program evaluating BETAXON in patients with glaucoma or ocular hypertension.
BETAXON is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently listed as active. The completed study was randomized, double blind, and controlled, enrolling 78 participants.
BETAXON has been evaluated in the Phase 3 trial NCT00061516, titled Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension. The trial is completed, enrolled 78 participants, and included patients as young as 1 week old.
Yes. BETAXON is also known as BETAXON (levobetaxolol HCl), so the two names refer to the same product. Levobetaxolol HCl is the chemical form of the small molecule developed by Alcon Inc. for glaucoma and ocular hypertension.